Sugi Predict

Sugi Predict / Compounds / SCHEMBL390400

SCHEMBL390400

SCHEMBL390400

NC(CCO)c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 1/20 0.46
▸ SLC6A3 Q01959 2/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ SCN4A P35499 2/20 0.42
▸ CYP2C9 P11712 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ SLC6A4 P31645 2/20 0.40
▸ AOC3 Q16853 1/20 0.40
▸ BRD4 O60885 1/20 0.39
▸ GABBR2 O75899 3/20 0.39
▸ GABBR1 Q9UBS5 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391358 1.00 ADRB2 (0.46) ADRB2SLC6A3SLC6A2SCN4ACYP2C9
SCHEMBL16649881 1.00 ADRB2 (0.46) ADRB2SLC6A3SLC6A2SCN4ACYP2C9
SCHEMBL390483 0.88 ADRB2 (0.43) ADRB2SLC6A3SCN4ACYP2C9MEN1
SCHEMBL1534396 0.82 SLC6A4 (0.50) ADRB2SLC6A3SLC6A2SCN4ACYP2C9
SCHEMBL1307450 0.82 ADRB2 (0.50) ADRB2SLC6A3SCN4ACYP2C9MEN1
SCHEMBL393010 0.82 ADRB2 (0.50) ADRB2SLC6A3SCN4ACYP2C9MEN1
SCHEMBL16649759 0.82 SLC6A4 (0.50) ADRB2SLC6A3SLC6A2SCN4ACYP2C9
SCHEMBL1308806 0.82 ADRB2 (0.50) ADRB2SLC6A3SCN4ACYP2C9MEN1
Hydrochloric Acid SCHEMBL1439141 0.80 ADRB2 (0.48) ADRB2SLC6A3SCN4ACYP2C9MEN1
Hydrochloric Acid SCHEMBL1439138 0.80 ADRB2 (0.48) ADRB2SLC6A3SCN4ACYP2C9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118185900-A Transaminase, preparation method and application thereof, and preparation method of amino-containing compound 爱斯特（成都）生物制药股份有限公司 2024-06-14 — — CN claimed
EP-3148998-B1 PROCESSES FOR THE PREPARATION OF AZD5363 AND NOVEL INTERMEDIATE USED THEREIN ASTRAZENECA AB (SE) 2018-07-11 — — EP claimed
US-9879017-B2 Processes for the preparation of AZD5363 and intermediate used therein ASTRAZENECA AB (SE) 2018-01-30 — — US claimed
US-20170210745-A1 Processes for the Preparation of AZD5363 and Novel Intermediate Used Therein ASTRAZENECA AB (SE) 2017-07-27 — — US claimed
EP-2201012-B1 PYRROLO[2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2014-06-25 — — EP claimed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US claimed
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
EP-4516778-A1 COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2025-03-05 — — EP disclosed
CN-118185900-A Transaminase, preparation method and application thereof, and preparation method of amino-containing compound 爱斯特（成都）生物制药股份有限公司 2024-06-14 — — CN disclosed
CN-118185900-A Transaminase, preparation method and application thereof, and preparation method of amino-containing compound 爱斯特（成都）生物制药股份有限公司 2024-06-14 — — CN disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
WO-2023210599-A1 COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE 日本新薬株式会社 2023-11-02 — — WO disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed
EP-1653961-A4 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORP (US) 2009-04-01 — — EP disclosed
EP-1653961-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 — — EP disclosed
WO-2005011700-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-02-10 — — WO disclosed
US-5760033-A INSECTICDES; MITICIDES NIPPON SODA CO., LTD (JP) 1998-06-02 — — US disclosed
EP-0675115-A1 HETEROCYCLIC DERIVATIVE AND PEST CONTROL AGENT NIPPON SODA CO., LTD. (JP) 1995-10-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SLC6A3 4750/4885SLC6A2 4458/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SLC6A3 4750/4885SLC6A2 4458/4885
US-20170210745-A1 Processes for the Preparation of AZD5363 and Novel Intermediate Used Therein JAK3, CDK3, STK3 ADRB2 2734/4885SLC6A3 1537/4885SLC6A2 4623/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 ADRB2 1387/4885SLC6A3 4759/4885SLC6A2 4605/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SLC6A3 4750/4885SLC6A2 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.